GLENMARK — Glenmark Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹628.43bn
- IN₹620.37bn
- IN₹169.83bn
Annual cashflow statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 14,412 | 8,685 | 5,692 | 13,992 | 19,847 |
| Depreciation | |||||
| Non-Cash Items | 3,004 | 8,607 | 3,790 | 4,960 | 21,169 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11,197 | -17,144 | -20,362 | -32,088 | -12,301 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 11,087 | 6,261 | -4,572 | -8,276 | 34,450 |
| Capital Expenditures | -7,901 | -6,078 | -9,149 | -7,507 | -13,577 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 4,568 | 793 | 54,758 | 7,528 | 745 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3,333 | -5,285 | 45,609 | 20.9 | -12,832 |
| Financing Cash Flow Items | -3,079 | -4,643 | -5,168 | -2,208 | -2,111 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -5,205 | -775 | -39,061 | 7,870 | -27,087 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,724 | 325 | 2,152 | 174 | -5,010 |